Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
О. В. Орлова, Д. В. Глазкова, E. V. Bogoslovskaya, German A. Shipulin, Sergey Mikhailovich Yudin
Abstract
Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its properties as a vaccine, including a high safety profile. In recent years, MVA has found its place as a vector for the creation of vaccines against various diseases. To date, a large number of vaccine candidates based on the MVA vector have already been developed, many of which have been tested in preclinical and clinical studies. We discuss data on the immunogenicity and efficacy of some of these vaccines.